Anti-DNase B Antibody Test: A Laboratory Specialist’s Complete Guide to Results and Interpretation

Written by a Board-Certified Laboratory Medicine Specialist (MD.PhD.)  ·  Updated April 2026

In this article

1. What is Anti-DNase B and why is it tested?
2. Specimen and assay method (Nephelometry)
3. Reference ranges by age
4. Clinical interpretation
5. Anti-DNase B vs. ASO — when each test matters
6. Precautions and limitations
7. Specialist’s perspective and conclusion
8. References and AI image prompts

Quick summary: The Anti-DNase B (anti-deoxyribonuclease B) antibody test detects immune responses to past Group A Streptococcus (GAS) infection, making it a critical tool for diagnosing post-streptococcal complications such as Acute Rheumatic Fever (ARF) and Post-Streptococcal Glomerulonephritis (PSGN). Because it complements the Antistreptolysin O (ASO) test — particularly for skin infections where ASO often fails to rise — the two are frequently ordered together to maximize diagnostic sensitivity. This article provides age-stratified reference ranges, detailed result interpretation, and practical clinical guidance from a laboratory medicine perspective.

1. What is Anti-DNase B and why is it tested?

Anti-DNase B is a serum antibody directed against DNase B (deoxyribonuclease B), an extracellular enzyme produced by Streptococcus pyogenes (Group A Streptococcus, GAS). Following a GAS infection, the immune system mounts an antibody response against this enzyme. Detecting that antibody response — even days to weeks after the acute infection has resolved — provides critical evidence of recent streptococcal exposure.

The test is particularly valuable because post-streptococcal complications can arise in the absence of classic symptoms. A patient who never sought care for a sore throat or skin infection may present weeks later with joint inflammation or hematuria, and the Anti-DNase B result can serve as the key diagnostic link to prior GAS infection.

Primary clinical indications include:

• Confirming recent or past GAS infection following pharyngitis, tonsillitis, or impetigo
• Evaluating suspected Acute Rheumatic Fever (ARF) — a major criterion for diagnosis requires serological evidence of prior GAS infection
• Supporting the diagnosis of Post-Streptococcal Glomerulonephritis (PSGN), especially following skin infections
• Supplementing the ASO test when ASO results are equivocal or negative
• Monitoring high-risk patients (e.g., children with recurrent GAS infections) for immunological burden

2. Specimen and assay method

The test is performed on a serum sample (whole blood collected without anticoagulant, allowed to clot, then centrifuged). Most modern laboratories use Nephelometry (NEP) — also written as Nephelometric Immunoassay — as the preferred analytical method.

In nephelometry, the patient’s Anti-DNase B antibodies bind to DNase B antigen reagent, forming immune complexes that scatter a focused beam of light. The intensity of light scatter is directly proportional to the antibody concentration in the sample, enabling precise quantitative results. Key advantages of this method include rapid turnaround time, high reproducibility, automation compatibility, and quantitative output (expressed in U/mL), which allows meaningful comparison of serial results over time.

3. Reference ranges by age

Anti-DNase B reference ranges are age-dependent. Children are more frequently exposed to GAS through school and daycare settings, so their baseline antibody levels tend to be higher than those of adults. The values below represent widely used clinical thresholds; always verify against your laboratory’s specific reagent system and local population norms.

Age group	Upper limit of normal	Unit	Interpretation if exceeded
Under 5 years	< 251	U/mL	Recent GAS exposure likely
5–17 years	< 376	U/mL	Elevated; clinical correlation required
18 years and older	< 301	U/mL	Elevated; prior GAS infection suspected

* Reference ranges vary by manufacturer, reagent lot, and geographic region. A single elevated result should always be interpreted alongside clinical history, not in isolation. Serial testing 2–3 weeks apart is recommended when the initial result is borderline — a rising titer is more diagnostically significant than any single value.

4. Clinical interpretation

Elevated High Anti-DNase B levels

An elevated Anti-DNase B titer indicates that the patient’s immune system has responded to GAS DNase B antigen, consistent with recent or prior GAS infection. Key conditions to consider:

• Acute Rheumatic Fever (ARF) — serological evidence of preceding GAS infection is a required element of the Jones Criteria; Anti-DNase B elevation fulfills this requirement even when throat cultures are negative
• Post-Streptococcal Glomerulonephritis (PSGN) — especially after GAS skin infections (impetigo), where Anti-DNase B is substantially more sensitive than ASO
• Streptococcal pharyngitis or tonsillitis — convalescent phase (1–2 weeks after symptom onset, peaking at 4–6 weeks)
• Streptococcal impetigo / pyoderma — the most important application distinguishing Anti-DNase B from ASO
• Invasive GAS infection — bacteremia, necrotizing fasciitis, streptococcal toxic shock syndrome
• Asymptomatic GAS carriage with active immune response

Antibody kinetics to remember: Anti-DNase B begins rising approximately 1–2 weeks after infection, reaches its peak at 4–6 weeks, and can remain elevated for several months. A patient presenting with ARF or PSGN six weeks after an unrecognized skin infection may still show a clearly elevated titer.

Normal / Low Normal or low Anti-DNase B levels

• Testing performed too early (within the first week of infection) — antibody production has not yet peaked
• Certain GAS strains that produce less DNase B or trigger a weaker humoral response
• Severe immunosuppression (malignancy, immunomodulatory therapy, HIV) — blunts antibody production
• Dilutional effect in protein-losing states such as nephrotic syndrome or protein-losing enteropathy
• Late testing — antibody titers declining after several months
• No recent GAS exposure

Important: A normal Anti-DNase B result does not rule out GAS infection, particularly when testing is performed in the early acute phase or in an immunocompromised host. Always consider paired ASO testing and repeat serology when clinical suspicion remains high.

5. Anti-DNase B vs. ASO — when each test matters

Antistreptolysin O (ASO) and Anti-DNase B are complementary, not interchangeable. Each detects antibodies against a different GAS enzyme, and the two tests differ meaningfully in their clinical utility depending on the site of infection.

ASO (antistreptolysin O)

• Best for: pharyngeal infections
• Rises reliably after throat GAS
• Less sensitive after skin GAS
• Streptolysin O inhibited by skin lipids

Anti-DNase B

• Best for: skin and pharyngeal infections
• Rises after impetigo / pyoderma
• Higher sensitivity for PSGN after skin GAS
• Remains elevated longer than ASO

When both tests are ordered simultaneously, combined sensitivity for detecting prior GAS infection approaches 95–98%, significantly higher than either test alone. Current guidelines from the American Heart Association for ARF diagnosis recommend checking both markers.

6. Precautions and limitations

Several factors can influence Anti-DNase B results and must be accounted for during clinical interpretation:

• Age-specific reference ranges are mandatory. Applying adult thresholds to a school-age child will generate spurious “positive” results. Always use the age-matched cut-off for the specific assay in use.
• A single result does not confirm active infection. Elevated Anti-DNase B reflects past immune exposure, not ongoing bacteremia. The presence of the antibody tells you the patient encountered GAS recently — not that the organism is still present.
• Serial testing adds critical diagnostic value. A fourfold or greater rise in titer between acute and convalescent specimens (collected 2–3 weeks apart) constitutes strong evidence of recent infection, even if the initial single result appears borderline.
• Protein-losing diseases reduce antibody concentrations. Nephrotic syndrome, protein-losing enteropathy, and severe malnutrition can lower measured immunoglobulin levels, potentially masking a true elevation. Clinical history is essential.
• Immunosuppressive therapy blunts the antibody response. Patients on systemic corticosteroids, chemotherapy, or biologics may mount a suboptimal antibody response despite significant infection.
• Antibodies persist for months. An elevated titer may reflect an infection that occurred weeks or even months before the current clinical presentation. Distinguishing this from a truly recent infection requires careful correlation with symptom timeline.
• This test cannot confirm active GAS bacteremia. If current invasive infection is suspected, blood cultures and throat swab cultures remain the gold standard.

Self-diagnosis caution: Anti-DNase B results should never be used for self-diagnosis or to initiate self-treatment. Interpretation requires clinical context, age-specific norms, and often paired testing with ASO and other markers. Always consult a qualified healthcare provider.

7. Specialist’s perspective and conclusion

In my day-to-day laboratory practice, the most commonly missed opportunity I observe is the failure to order Anti-DNase B alongside ASO when post-streptococcal complications are suspected after a skin infection. Clinicians who rely on ASO alone will miss a meaningful proportion of PSGN cases following impetigo, because streptolysin O is naturally inhibited by skin lipids and rarely elicits a robust ASO response after cutaneous GAS disease.

Two practical points I emphasize consistently:

1. Always order both ASO and Anti-DNase B in suspected ARF or PSGN — the combination dramatically increases your detection rate and is recommended by international guidelines. If your institution’s order set prompts you to choose one, choose Anti-DNase B for skin-infection-related workup and ASO for pharyngeal-infection-related workup; if unsure, order both.
2. Interpret the trend, not just the number. A patient with an Anti-DNase B of 320 U/mL in an adult is elevated — but whether that represents a fresh immune response peaking at week four, or a slowly declining titer from a months-old infection, changes the clinical management entirely. Paired convalescent serology, collected 2–3 weeks later, is the single most informative step you can take after a borderline-positive result.

Used thoughtfully, Anti-DNase B is an elegant, non-invasive window into the patient’s recent immunological history with GAS — one of the most common and potentially serious bacterial pathogens in the world.

Author profile

Laboratory Medicine Specialist, MD.PhD.

Board-certified specialist in clinical pathology and laboratory medicine with expertise in infectious disease serology, immunoassay interpretation, and post-streptococcal disease diagnostics. All clinical recommendations in this article are grounded in current international guidelines and reflect evidence available as of April 2026. Medical decisions should always be made in consultation with a qualified clinician.

[MD.PhD.] Understanding the HE4 Blood Test – MedLab Insight

[MD.PhD.] Understanding the CA19-9 Blood Test – MedLab Insight

References

1. Gewitz, M. H., Baltimore, R. S., Tani, L. Y., et al. (2015). Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography. Circulation, 131(20), 1806–1818. https://doi.org/10.1161/CIR.0000000000000205
2. Carapetis, J. R., Beaton, A., Cunningham, M. W., et al. (2016). Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers, 2, 15084.
3. Rodriguez-Iturbe, B., & Musser, J. M. (2008). The current state of post-streptococcal glomerulonephritis. Journal of the American Society of Nephrology, 19(10), 1855–1864.
4. Steer, A. C., Danchin, M. H., & Carapetis, J. R. (2007). Group A streptococcal infections in children. Journal of Paediatrics and Child Health, 43(4), 203–213.
5. UpToDate. (2025). Antistreptolysin O and anti-DNase B: Diagnostic approach to streptococcal infection. Wolters Kluwer. https://www.uptodate.com
6. Mayo Clinic Laboratories. (2024). Anti-DNase B antibody, serum. https://www.mayocliniclabs.com
7. Centers for Disease Control and Prevention. (2024). Group A Streptococcal (GAS) disease. https://www.cdc.gov/groupastrep
8. Group A Strep Infection | Group A Strep | CDC